Glaukos

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Glaukos and other ETFs, options, and stocks.

About GKOS

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology.

CEO

Thomas William Burns

CEOThomas William Burns

Employees

995

Employees995

Headquarters

Aliso Viejo, California

HeadquartersAliso Viejo, California

Founded

1998

Founded1998

Employees

995

Employees995

GKOS Key Statistics

Market cap

7.44B

Market cap7.44B

Price-Earnings ratio

-35.80

Price-Earnings ratio-35.80

Dividend yield

—

Dividend yield—

Average volume

886.91K

Average volume886.91K

High today

$120.19

High today$120.19

Low today

$114.96

Low today$114.96

Open price

$119.69

Open price$119.69

Volume

1.12M

Volume1.12M

52 Week high

$161.58

52 Week high$161.58

52 Week low

$73.16

52 Week low$73.16

Stock Snapshot

As of today, Glaukos(GKOS) shares are valued at $117.10. The company's market cap stands at 7.44B, with a P/E ratio of -35.80.

On 2026-02-20, Glaukos(GKOS) stock traded between a low of $114.96 and a high of $120.19. Shares are currently priced at $117.10, which is +1.9% above the low and -2.6% below the high.

Glaukos(GKOS) shares are trading with a volume of 1.12M, against a daily average of 886.91K.

In the last year, Glaukos(GKOS) shares hit a 52-week high of $161.58 and a 52-week low of $73.16.

GKOS News

Benzinga 2d

These Analysts Boost Their Forecasts On Glaukos Following Q4 Results

Glaukos Corp (NYSE:GKOS) reported mixed results for the fourth quarter on Tuesday. The company posted quarterly losses of 28 cents per share which missed the an...

Simply Wall St 2d

Assessing Glaukos Valuation After Strong Growth Guidance And Intangible Asset Impairment

Glaukos (GKOS) has drawn fresh attention after reporting fourth quarter and full year 2025 results, issuing 2026 sales guidance of US$600 million to US$620 mill...

The Motley Fool 2d

Glaukos Q4 2025 Earnings Call Transcript

Image source: The Motley Fool. Feb. 17, 2026 at 4:30 p.m. ET Call participants Chairman & Chief Executive Officer — Thomas William Burns Chief Financial Office...

Analyst ratings

88%

of 16 ratings

Buy

87.5%

Hold

6.3%

Sell

6.3%

More GKOS News

TipRanks 3d

Glaukos Reports Record Q4 Sales, Reaffirms 2026 Outlook

Glaukos ( (GKOS) ) just unveiled an announcement. On February 17, 2026, Glaukos reported record fourth-quarter 2025 net sales of $143.1 million, up 36% year ov...

TipRanks 3d

Glaukos reports Q4 adjusted EPS (28c), consensus (30c)

Reports Q4 revenue $143.1M, consensus $137.02M. “Our record fourth quarter results cap off a highly successful year of global execution across our key commercia...

People also own

Based on the portfolios of people who own GKOS. This list is generated using Robinhood data, and it’s not a recommendation.

Marvell Technology

CRISPR

AMD

Taiwan Semiconductor Manu…

Micron Technology

IBM

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.